Idogen

0,151SEK -32,29 %
Vær den første som følger denne virksomhed

Idogen (Nasdaq First Growth Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body’s own cells or tissue. The company’s most advanced project, IDO 8, is designed to restore the efficacy of hemophilia drugs in patients who have developed neutralizing antibodies. The company’s second project, IDO T, is being developed to prevent kidney transplant rejection.

Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
First North Stockholm
IDOGEN
Daglig lav / høj pris
0,151 / 0,253 SEK
Markedsværdi
15,76 mio. SEK
Aktieomsætning
2,66 mio. SEK
Volumen
13 mio.